WHO Model Formulary: International Standards for Essential Generics
You might assume that choosing medicines for a hospital or a village clinic is straightforward, but the stakes could not be higher. In 2023, the World Health Organization updated its WHO Model List of Essential Medicines, widely regarded as the global standard for identifying priority medicines needed in functioning health systems. While often called a "formulary," this tool serves a distinct purpose: it tells nations exactly which essential generics and brand medicines are non-negotiable for public health survival. As of March 2026, understanding this list isn't just for policymakers; it shapes everything from your local pharmacy's stock to the life-saving treatments available during a pandemic.
Defining the Standard: What Is the WHO Model List?
There is frequent confusion between a "list" and a "formulary." A hospital formulary is a practical shopping menu used by doctors and insurers, often including pricing tiers and approval workflows. The WHO Model List of Essential Medicines (EML) differs fundamentally. It was first established in 1977 and now stands in its 23rd edition. Its job is purely scientific and ethical: to select medicines that satisfy the priority health care needs of populations globally. These selections rely on evidence, not profit margins. The 2023 update released in July included 591 medicines covering 369 disease indications, ensuring that when a government designs their own health plan, they aren't starting from scratch.
The list splits into two distinct sections to manage complexity:
| Structure of the WHO Model List | |
|---|---|
| Core List | Minimum medicine needs for a basic health-care system. Includes the most efficacious, safe, and cost-effective medicines for priority conditions. |
| Complementary List | Includes medicines requiring specialized diagnostic facilities or specialist medical care/training. |
This separation ensures that rural clinics in low-income regions know they can expect the core drugs (like antibiotics for pneumonia), while hospitals have guidance on complex therapies like chemotherapy agents.
The Science Behind Selection Criteria
How does a medicine earn a spot on this prestigious list? It isn't a popularity contest. The selection relies on rigorous data. An independent Expert Committee meets to review applications. For the 2023 list, 25 experts from 18 countries convened in March to sift through 217 applications for new inclusions. They utilize a standardized scoring system that demands high marks in four domains:
- Public Health Relevance (30%): Does the medicine address a disease affecting significant numbers of people? The threshold is typically a prevalence of at least 100 cases per 100,000 population.
- Efficacy and Safety (30%): Must be backed by randomized controlled trials graded at level 1a or 1b.
- Comparative Cost-Effectiveness (25%): The cost per quality-adjusted life year usually must be below three times the GDP per capita.
- Programmatic Feasibility (15%): Can health workers actually store, transport, and administer this medicine reliably?
A medicine requires a minimum score of 7 out of 10 in each domain and an overall average of 7.5. This math-heavy approach filters out drugs that might look good on paper but fail in reality.
The Role of Essential Generics
Here is where the conversation gets interesting for affordability advocates. Of the 591 medicines listed in 2023, 273 of them-roughly 46%-are explicitly identified as generics. The WHO pushes hard on generic substitution policies because they drive prices down. Consider the example of HIV antiretroviral therapy. In 2008, the median price was $1,076 per patient per year. By 2022, thanks largely to the push for generic competition aligned with WHO recommendations, that price dropped to $119. This 89% reduction allowed treatment scale-up from 800,000 people to nearly 30 million globally.
However, cheap does not mean low quality. The WHO model mandates strict assurance. About 92% of generic medicines on the list require WHO Prequalification status. This means manufacturers must prove bioequivalence, showing that the generic performs within 80-125% confidence intervals compared to the original brand product. For narrow therapeutic index drugs, those limits tighten to 90-111%. Without this scrutiny, patients risk taking ineffective pills that waste money and time.
Global Adoption and Real-World Challenges
Paper lists are useless if shelves remain empty. Over 150 countries have established National Essential Medicines Lists based on the WHO model. In Ghana, for instance, the National Health Insurance Authority adopted these principles and saw a 29% reduction in out-of-pocket medicine costs between 2018 and 2022. Pharmacists there reported much improved availability of generics for diabetes and hypertension. Yet, success stories come with caveats. A 2022 survey of 1,250 facilities in Nigeria found only 41% of the essential medicines on their national list were consistently available. Stockouts averaged 58 days per year.
The issue isn't usually the list itself, but the supply chain. In 2020-2022, during global disruptions, 62% of low-income countries reported shortages of essential antibiotics. Furthermore, market concentration creates vulnerability. Roughly 78% of generic medicine production sits in just three countries: India, China, and the United States. If logistics in these regions stall, the global network suffers.
Differentiated experiences also appear by region. High-income nations rarely use the WHO list for domestic decisions. A 2023 survey showed only 22% of US hospital pharmacy directors consult it regularly, preferring compendia like Micromedex. However, in Africa, 92% of countries base their national lists on the WHO standard. This gap highlights a disconnect: rich nations invent new technologies, while developing nations rely on the WHO framework to secure the basics.
Criticism and Industry Influence
No standard is immune to critique. Some experts argue that the selection process leans too heavily on industry-funded trials. Data suggests that 45% of supporting evidence in 2023 came from such trials, up from 28% in 2015. Dr. Joel Lexchin of York University noted this risks compromising independence. The WHO responded by tightening conflict-of-interest policies, mandating 100% disclosure from committee members.
Another criticism focuses on innovation speed. Only 12% of novel therapeutics approved between 2018-2022 made it onto the 2023 list, whereas high-income country formularies included 35-45%. Critics argue this leaves poorer nations waiting longer for modern cures. The defense is pragmatic: new drugs are expensive, and the list prioritizes public health burden over novelty. There is no point recommending a cutting-edge drug if a clinic cannot afford power outlets to run the freezers required to store it.
Future Directions and Implementation
Looking toward 2030, the strategy is shifting from pure selection to active stewardship. The WHO launched the Essential Medicines App in September 2023, downloaded 127,000 times across 158 countries. This digital move aims to put the list directly in a doctor's hand rather than in a dusty binder.
New guidelines released in February 2024 target antimicrobial resistance (AMR). Draft rules now require formulary committees to implement "antibiotic stewardship tiers" similar to those used in US insurance plans. Additionally, biosimilars are finally getting specific criteria. In the past, biological drugs were excluded due to complexity. Now, seven monoclonal antibodies are included, requiring tight bioequivalence ranges of 85-115%. This reflects the changing nature of disease management as we move from infectious diseases to chronic conditions.
The ultimate goal remains Universal Health Coverage. The WHO targets increasing essential medicine availability in primary care from the current 65% to 80% by 2030. To achieve this, funding models need to evolve. Currently, only 31% of low-income countries allocate the recommended 15% of total health expenditure to pharmaceutical budgets. Until financing matches the list, the standard remains aspirational.
Is the WHO Model List legally binding?
No, the list is not legally binding. It serves as a technical reference for countries developing their own National Essential Medicines Lists (NEMLs). Governments voluntarily adapt it to fit local disease burdens and economic capabilities.
Why are generics emphasized in the WHO Model List?
Generics account for about 46% of the list. They are emphasized because they offer equivalent therapeutic effects to branded drugs at significantly lower costs, enabling wider access in resource-limited settings. The list strictly requires quality prequalification to ensure these lower-cost options are not substandard.
How often is the WHO Model List updated?
The list is reviewed and updated biennially (every two years). The 23rd edition was published in July 2023, and updates continue based on emerging evidence and public health needs.
Can doctors prescribe medicines not on the list?
Yes, physicians can always prescribe off-list medications based on individual patient needs. However, public procurement and reimbursement programs typically prioritize medicines on the essential list to ensure cost-efficiency.
What is the difference between the Core and Complementary lists?
The Core List includes medicines for a basic health system accessible to everyone. The Complementary List adds medicines that need specialist care, diagnostics, or training, making them suitable primarily for hospital-level care.
